Another option is a somatostatin analogue, such as octreotide, which reduces tumour number and size, reduces serum gastrin concentrations indirectly, and reduces circulating chromogranin A (CgA) [18-21], which is a marker of ECL-cell mass and activity [22-24]. The gene discussed is GAST; the disease is neoplasm.